

Michael S Conte

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1973533/publications.pdf>

Version: 2024-02-01

163
papers

11,927
citations

34105
52
h-index

28297
105
g-index

165
all docs

165
docs citations

165
times ranked

7779
citing authors

#	ARTICLE	IF	CITATIONS
1	Pedal arterial calcification score is associated with the risk of major amputation in chronic limb-threatening ischemia. Journal of Vascular Surgery, 2022, 75, 270-278.e3.	1.1	16
2	Risk factors for venous thromboembolism after vascular surgery and implications for chemoprophylaxis strategies. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2022, 10, 585-593.e2.	1.6	7
3	A systematic review of patient-reported outcome measures patients with chronic limb-threatening ischemia. Journal of Vascular Surgery, 2022, 75, 1762-1775.	1.1	7
4	Patient-Reported Outcome Measures in Symptomatic, Non-“Limb-Threatening Peripheral Artery Disease: A State-of-the-Art Review. Circulation: Cardiovascular Interventions, 2022, 15, CIRCINTERVENTIONS121011320.	3.9	5
5	17R/S-Benzo-RvD1, a synthetic resolvin D1 analogue, attenuates neointimal hyperplasia in a rat model of acute vascular injury. PLoS ONE, 2022, 17, e0264217.	2.5	4
6	Analysis of a Machine Learning-“Based Risk Stratification Scheme for Chronic Limb-Threatening Ischemia. JAMA Network Open, 2022, 5, e223424.	5.9	3
7	Applicability of the Vascular Quality Initiative mortality prediction model for infrainguinal revascularization in a tertiary limb preservation center population. Journal of Vascular Surgery, 2022, 76, 505-512.e2.	1.1	6
8	Society for Vascular Surgery appropriate use criteria for management of intermittent claudication. Journal of Vascular Surgery, 2022, 76, 3-22.e1.	1.1	37
9	Peripheral arterial disease (pathophysiology, presentation, prevention/management). , 2022, , 361-375.		0
10	Pedal arterial calcification score is associated with hemodynamic change and major amputation after infrainguinal revascularization for chronic limb-threatening ischemia. Journal of Vascular Surgery, 2022, 76, 1688-1697.e3.	1.1	10
11	Meaningful change in 6-minute walk in people with peripheral artery disease. Journal of Vascular Surgery, 2021, 73, 267-276.e1.	1.1	36
12	A novel preoperative risk score for nonhome discharge after elective thoracic endovascular aortic repair. Journal of Vascular Surgery, 2021, 73, 1549-1556.	1.1	3
13	Living in a Food Desert is Associated with 30-day Readmission after Revascularization for Chronic Limb-Threatening Ischemia. Annals of Vascular Surgery, 2021, 70, 36-42.	0.9	10
14	A limb is a peninsula and no clinician is an island: Introducing the American Limb Preservation Society (ALPS). Foot & Ankle Surgery Techniques, Reports & Cases, 2021, 1, 100005.	0.1	2
15	Closure device use for common femoral artery antegrade access is higher risk than retrograde access. Annals of Vascular Surgery, 2021, 76, 49-58.	0.9	3
16	Endovascular interventions for claudication do not meet minimum standards for the Society for Vascular Surgery efficacy guidelines. Journal of Vascular Surgery, 2021, 73, 1693-1700.e3.	1.1	25
17	The Global Limb Anatomic Staging System is associated with outcomes of infrainguinal revascularization in chronic limb threatening ischemia. Journal of Vascular Surgery, 2021, 73, 2009-2020.e4.	1.1	23
18	Advances in Revascularization for Peripheral Artery Disease: Revascularization in PAD. Circulation Research, 2021, 128, 1885-1912.	4.5	77

#	ARTICLE	IF	CITATIONS
19	Precision Medicine Enables More TNM-Like Staging in Patients With Chronic Limb Threatening Ischemia. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 709904.	2.4	3
20	Depression Predicts Non-Home Discharge After Abdominal Aortic Aneurysm Repair. <i>Annals of Vascular Surgery</i> , 2021, 74, 131-140.	0.9	8
21	Patients with depression are less likely to go home after critical limb revascularization. <i>Journal of Vascular Surgery</i> , 2021, 74, 178-186.e2.	1.1	10
22	Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial. <i>Circulation</i> , 2021, 144, 1104-1116.	1.6	25
23	The Global Limb Anatomic Staging System (GLASS) for CLTI: Improving Inter-Observer Agreement. <i>Journal of Clinical Medicine</i> , 2021, 10, 3454.	2.4	14
24	Invasive treatment of claudication: Time for better measures and better controls. <i>Journal of Vascular Surgery</i> , 2021, 74, 505.	1.1	1
25	Contemporary Experience with Paravisceral Aortic Aneurysm (PVAAA) Repair in a Tertiary Center. <i>Annals of Vascular Surgery</i> , 2021, 75, 368-379.	0.9	4
26	A critical appraisal of registry-based objective performance goals in peripheral arterial disease. <i>Journal of Vascular Surgery</i> , 2021, 74, 1008-1012.	1.1	3
27	Understanding value and patient complexity among common inpatient vascular surgery procedures. <i>Journal of Vascular Surgery</i> , 2021, 74, 1343-1353.e2.	1.1	1
28	Risk score for nonhome discharge after lower extremity bypass. <i>Journal of Vascular Surgery</i> , 2020, 71, 889-895.	1.1	5
29	Validation of randomized controlled trial-derived models for the prediction of postintervention outcomes in chronic limb-threatening ischemia. <i>Journal of Vascular Surgery</i> , 2020, 71, 869-879.	1.1	7
30	Reply. <i>Journal of Vascular Surgery</i> , 2020, 71, 348-349.	1.1	0
31	Appropriate use of revascularization for claudication. <i>Journal of Vascular Surgery</i> , 2020, 71, 131.	1.1	2
32	Comparing 6-minute walk versus treadmill walking distance as outcomes in randomized trials of peripheral artery disease. <i>Journal of Vascular Surgery</i> , 2020, 71, 988-1001.	1.1	25
33	Oral Resolvin D1 attenuates early inflammation but not intimal hyperplasia in a rat carotid angioplasty model. <i>Prostaglandins and Other Lipid Mediators</i> , 2020, 146, 106401.	1.9	9
34	Impact of the coronavirus disease 2019 pandemic on an academic vascular practice and a multidisciplinary limb preservation program. <i>Journal of Vascular Surgery</i> , 2020, 72, 1850-1855.	1.1	30
35	Patient complexity by surgical specialty does not correlate with work relative value units. <i>Surgery</i> , 2020, 168, 371-378.	1.9	21
36	External validation of the Vascular Quality Initiative prediction model for survival in no-option chronic limb-threatening ischemia patients. <i>Journal of Vascular Surgery</i> , 2020, 72, 1659-1666.e1.	1.1	10

#	ARTICLE	IF	CITATIONS
37	Increased Reintervention After Infrainguinal Revascularization for Chronic Limb-Threatening Ischemia in Women. <i>Annals of Vascular Surgery</i> , 2020, 69, 307-316.	0.9	6
38	Editor's Choice "Relationship Between Global Limb Anatomic Staging System (GLASS) and Clinical Outcomes Following Revascularisation for Chronic Limb Threatening Ischaemia in the Bypass Versus Angioplasty in Severe Ischaemia of the Leg (BASIL)-1 Trial. <i>European Journal of Vascular and Endovascular Surgery</i> , 2020, 60, 687-695.	1.5	43
39	Specialized pro-resolving lipid mediators in cardiovascular disease, diagnosis, and therapy. <i>Advanced Drug Delivery Reviews</i> , 2020, 159, 170-179.	13.7	22
40	Treatment With a Marine Oil Supplement Alters Lipid Mediators and Leukocyte Phenotype in Healthy Patients and Those With Peripheral Artery Disease. <i>Journal of the American Heart Association</i> , 2020, 9, e016113.	3.7	27
41	Clinical Effectiveness and Resource Utilization of Surgery versus Endovascular Therapy for Chronic Limb-Threatening Ischemia. <i>Annals of Vascular Surgery</i> , 2020, 68, 510-521.	0.9	0
42	Reply. <i>Journal of Vascular Surgery</i> , 2020, 72, 1831-1832.	1.1	0
43	Pedal Arterial Calcification Score Correlates With Risk of Major Amputation in Chronic Limb-Threatening Ischemia. <i>Journal of Vascular Surgery</i> , 2020, 72, e337.	1.1	3
44	Implementing global chronic limb-threatening ischemia guidelines in clinical practice: Utility of the Society for Vascular Surgery Threatened Limb Classification System (Wifl). <i>Journal of Vascular Surgery</i> , 2020, 72, 1451-1452.	1.1	10
45	Association of Health Status Scores With Cardiovascular and Limb Outcomes in Patients With Symptomatic Peripheral Artery Disease: Insights From the EUCLID (Examining Use of Ticagrelor in) Tj ETQq1 1 0.784314 rgBT ₇ /Overlo e016573.	3.7	7
46	Circulating exosomes from patients with peripheral artery disease influence vascular cell migration and contain distinct microRNA cargo. <i>JVS Vascular Science</i> , 2020, 1, 28-41.	1.1	23
47	Antegrade common femoral artery closure device use is associated with decreased complications. <i>Journal of Vascular Surgery</i> , 2020, 72, 1610-1617.e1.	1.1	9
48	Where do We Go to in the Treatment of Acute Limb Ischaemia?. <i>European Journal of Vascular and Endovascular Surgery</i> , 2020, 59, 171-172.	1.5	1
49	Natural history of acute pediatric iliofemoral artery thrombosis treated with anticoagulation. <i>Journal of Vascular Surgery</i> , 2020, 72, 2027-2034.	1.1	4
50	Building a Global Alliance in Vascular Surgery. <i>European Journal of Vascular and Endovascular Surgery</i> , 2019, 58, 318-319.	1.5	2
51	Critical review and evidence implications of paclitaxel drug-eluting balloons and stents in peripheral artery disease. <i>Journal of Vascular Surgery</i> , 2019, 70, 3-7.	1.1	26
52	Building a global alliance in vascular surgery. <i>Journal of Vascular Surgery</i> , 2019, 70, 663-664.	1.1	2
53	Global vascular guidelines on the management of chronic limb-threatening ischemia. <i>Journal of Vascular Surgery</i> , 2019, 69, 3S-125S.e40.	1.1	841
54	A systematic review and meta-analysis of revascularization outcomes of infrainguinal chronic limb-threatening ischemia. <i>European Journal of Vascular and Endovascular Surgery</i> , 2019, 58, S110-S119.	1.5	32

#	ARTICLE	IF	CITATIONS
55	Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia. <i>European Journal of Vascular and Endovascular Surgery</i> , 2019, 58, S1-S109.e33.	1.5	741
56	A systematic review and meta-analysis of revascularization outcomes of infrainguinal chronic limb-threatening ischemia. <i>Journal of Vascular Surgery</i> , 2019, 69, 126S-136S.	1.1	69
57	Survival prediction in patients with chronic limb-threatening ischemia who undergo infrainguinal revascularization. <i>European Journal of Vascular and Endovascular Surgery</i> , 2019, 58, S120-S134.e3.	1.5	23
58	Using the Society for Vascular Surgery Wound, Ischemia, and foot Infection classification to identify patients most likely to benefit from revascularization. <i>Journal of Vascular Surgery</i> , 2019, 70, 776-785.e1.	1.1	26
59	Fish Oil Increases Specialized Pro-resolving Lipid Mediators in PAD (The OMEGA-PAD II Trial). <i>Journal of Surgical Research</i> , 2019, 238, 164-174.	1.6	38
60	Survival prediction in patients with chronic limb-threatening ischemia who undergo infrainguinal revascularization. <i>Journal of Vascular Surgery</i> , 2019, 69, 137S-151S.e3.	1.1	60
61	Interventions for lower extremity peripheral artery disease. <i>Nature Reviews Cardiology</i> , 2018, 15, 332-350.	13.7	69
62	Effect of a Home-Based Exercise Intervention of Wearable Technology and Telephone Coaching on Walking Performance in Peripheral Artery Disease. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1665.	7.4	151
63	Resolvin D1 decreases abdominal aortic aneurysm formation by inhibiting NETosis in a mouse model. <i>Journal of Vascular Surgery</i> , 2018, 68, 93S-103S.	1.1	48
64	A systematic review and meta-analysis of revascularization outcomes of infrainguinal chronic limb-threatening ischemia. <i>Journal of Vascular Surgery</i> , 2018, 68, 624-633.	1.1	133
65	Prognostic value of the Society for Vascular Surgery Wound, Ischemia, and foot Infection (Wifl) classification in patients with no-option chronic limb-threatening ischemia. <i>Journal of Vascular Surgery</i> , 2018, 68, 1104-1113.e1.	1.1	21
66	Perivascular delivery of resolvin D1 inhibits neointimal hyperplasia in a rabbit vein graft model. <i>Journal of Vascular Surgery</i> , 2018, 68, 188S-200S.e4.	1.1	31
67	Pro-resolving lipid mediators in vascular disease. <i>Journal of Clinical Investigation</i> , 2018, 128, 3727-3735.	8.2	58
68	Perivascular delivery of resolvin D1 inhibits neointimal hyperplasia in a rat model of arterial injury. <i>Journal of Vascular Surgery</i> , 2017, 65, 207-217.e3.	1.1	49
69	Cryopreserved saphenous vein as a last-ditch conduit for limb salvage. <i>Journal of Vascular Surgery</i> , 2017, 66, 844-849.	1.1	27
70	Biosynthesis of proresolving lipid mediators by vascular cells and tissues. <i>FASEB Journal</i> , 2017, 31, 3393-3402.	0.5	41
71	Data, guidelines, and practice of revascularization for claudication. <i>Journal of Vascular Surgery</i> , 2017, 66, 911-915.	1.1	8
72	Determinants of midterm functional outcomes, wound healing, and resources used in a hospital-based limb preservation program. <i>Journal of Vascular Surgery</i> , 2017, 66, 1765-1774.	1.1	30

#	ARTICLE	IF	CITATIONS
73	Relationship between the omega-3 index and specialized pro-resolving lipid mediators in patients with peripheral arterial disease taking fish oil supplements. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1289-1295.	1.5	19
74	Resolution of vascular injury: Specialized lipid mediators and their evolving therapeutic implications. <i>Molecular Aspects of Medicine</i> , 2017, 58, 72-82.	6.4	48
75	Novel association between bone mineral density scores and the prevalence of peripheral artery disease in both sexes. <i>Vascular Medicine</i> , 2017, 22, 13-20.	1.5	12
76	Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease. <i>Circulation</i> , 2017, 135, 241-250.	1.6	111
77	Unidirectional and sustained delivery of the proresolving lipid mediator resolvin D1 from a biodegradable thin film device. <i>Journal of Biomedical Materials Research - Part A</i> , 2017, 105, 31-41.	4.0	23
78	Aspirin-triggered resolvin D1 attenuates PDGF-induced vascular smooth muscle cell migration via the cyclic adenosine monophosphate/protein kinase A (cAMP/PKA) pathway. <i>PLoS ONE</i> , 2017, 12, e0174936.	2.5	30
79	Society for Vascular Surgery limb stage and patient risk correlate with outcomes in an amputation prevention program. <i>Journal of Vascular Surgery</i> , 2016, 63, 1563-1573.e2.	1.1	77
80	Design and Rationale of the Best Endovascular Versus Best Surgical Therapy for Patients With Critical Limb Ischemia (BESTâ€œCLI) Trial. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	158
81	Dâ€œseries resolvins inhibit murine abdominal aortic aneurysm formation and increase M2 macrophage polarization. <i>FASEB Journal</i> , 2016, 30, 4192-4201.	0.5	88
82	Critical Limb Ischemia: Current Trends and Future Directions. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	167
83	Predictors of major amputation despite patent bypass grafts. <i>Journal of Vascular Surgery</i> , 2016, 63, 1279-1288.	1.1	27
84	Reversible cerebral vasoconstriction syndrome is a rare cause of stroke after carotid endarterectomy. <i>Journal of Vascular Surgery</i> , 2016, 64, 1847-1850.	1.1	12
85	Bypass surgery versus endovascular interventions in severe or critical limb ischemia. <i>Journal of Vascular Surgery</i> , 2016, 63, 244-253.e11.	1.1	64
86	Abstract 314: Development of a Nanotube-coated Nitinol Stent for Delivery of Resolvin D1. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, .	2.4	0
87	Primary Stenting in Femoropopliteal Occlusive Diseaseâ€œâ€œ What Is the Appropriate Role? â€œ. <i>Circulation Journal</i> , 2015, 79, 704-711.	1.6	10
88	Shortâ€œTerm, Highâ€œDose Fish Oil Supplementation Increases the Production of Omegaâ€œ3 Fatty Acidâ€œDerived Mediators in Patients With Peripheral Artery Disease (the OMEGAâ€œPAD I Trial). <i>Journal of the American Heart Association</i> , 2015, 4, e002034.	3.7	64
89	Functional Outcomes After Lower Extremity Revascularization in Nursing Home Residents. <i>JAMA Internal Medicine</i> , 2015, 175, 951.	5.1	42
90	Risk Factors for 30-Day Hospital Readmission in Patients Undergoing Treatment for Peripheral Artery Disease. <i>Vascular and Endovascular Surgery</i> , 2015, 49, 69-74.	0.7	15

#	ARTICLE	IF	CITATIONS
91	Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: Management of asymptomatic disease and claudication. Journal of Vascular Surgery, 2015, 61, 2S-41S.e1.	1.1	624
92	A systematic review for the screening for peripheral arterial disease in asymptomatic patients. Journal of Vascular Surgery, 2015, 61, 42S-53S.	1.1	87
93	A systematic review of treatment of intermittent claudication in the lower extremities. Journal of Vascular Surgery, 2015, 61, 54S-73S.	1.1	86
94	Introduction. Journal of Vascular Surgery, 2015, 61, 1S.	1.1	69
95	Evaluation and Treatment of Patients With Lower Extremity Peripheral Artery Disease. Journal of the American College of Cardiology, 2015, 65, 931-941.	2.8	269
96	Surgical Intervention for Peripheral Arterial Disease. Circulation Research, 2015, 116, 1614-1628.	4.5	99
97	The vascular surgeon-scientist: A 15-year report of the Society for Vascular Surgery Foundation/National Heart, Lung, and Blood Institute-mentored Career Development Award Program. Journal of Vascular Surgery, 2015, 61, 1050-1057.e3.	1.1	21
98	Systemic delivery of proresolving lipid mediators resolvin D ₂ and maresin 1 attenuates intimal hyperplasia in mice. FASEB Journal, 2015, 29, 2504-2513.	0.5	88
99	The natural history of untreated severe or critical limb ischemia. Journal of Vascular Surgery, 2015, 62, 1642-1651.e3.	1.1	271
100	Nonrevascularization-based treatments in patients with severe or critical limb ischemia. Journal of Vascular Surgery, 2015, 62, 1330-1339.e13.	1.1	27
101	Analysis of nutritional habits and intake of polyunsaturated fatty acids in veterans with peripheral arterial disease. Vascular Medicine, 2015, 20, 432-438.	1.5	10
102	Outcomes of Neuroischemic Wounds Treated by a Multidisciplinary Amputation Prevention Service. Annals of Vascular Surgery, 2015, 29, 534-542.	0.9	56
103	Advancing beyond the "heart-healthy diet" for peripheral arterial disease. Journal of Vascular Surgery, 2015, 61, 265-274.	1.1	39
104	Vein graft failure. Journal of Vascular Surgery, 2015, 61, 203-216.	1.1	110
105	Abstract 285: Rapid Change In Red Blood Cell PUFA Composition With High-dose Fish Oil Supplementation In Patients With Peripheral Artery Disease (PAD).. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, .	2.4	0
106	The Pro-Resolving Lipid Mediator Maresin 1 (MaR1) Attenuates Inflammatory Signaling Pathways in Vascular Smooth Muscle and Endothelial Cells. PLoS ONE, 2014, 9, e113480.	2.5	79
107	Relationship between kidney disease and endothelial function in peripheral artery disease. Journal of Vascular Surgery, 2014, 60, 1605-1611.	1.1	10
108	Clinical Trials in Peripheral Vascular Disease. Circulation, 2014, 130, 1812-1819.	1.6	40

#	ARTICLE	IF	CITATIONS
109	Safety and feasibility of adjunctive dexamethasone infusion into the adventitia of the femoropopliteal artery following endovascular revascularization. <i>Journal of Vascular Surgery</i> , 2014, 59, 1016-1024.	1.1	35
110	Short-term physical inactivity impairs vascular function. <i>Journal of Surgical Research</i> , 2014, 190, 672-682.	1.6	76
111	The Society for Vascular Surgery Lower Extremity Threatened Limb Classification System: Risk stratification based on Wound, Ischemia, and foot Infection (Wifl). <i>Journal of Vascular Surgery</i> , 2014, 59, 220-234.e2.	1.1	1,106
112	Clinical correlates of red blood cell omega-3 fatty acid content in male veterans with peripheral arterial disease. <i>Journal of Vascular Surgery</i> , 2014, 60, 1325-1331.	1.1	9
113	Factors associated with primary vein graft occlusion in a multicenter trial with mandated ultrasound surveillance. <i>Journal of Vascular Surgery</i> , 2014, 59, 996-1002.	1.1	29
114	Vitamin D deficiency is associated with mortality and adverse vascular access outcomes in patients with end-stage renal disease. <i>Journal of Vascular Surgery</i> , 2014, 60, 176-183.	1.1	17
115	Abstract 134: Short-Term, High-Dose Fish Oil Supplementation Increases the Production of Downstream n-3 Fatty Acid Metabolites in Patients With Peripheral Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, .	2.4	0
116	Abstract 318: Determinants of Red Blood Cell Omega-3-Fatty Acid Content in Patients With Peripheral Arterial Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, .	2.4	0
117	Critical appraisal of surgical revascularization for critical limb ischemia. <i>Journal of Vascular Surgery</i> , 2013, 57, 8S-13S.	1.1	78
118	Thirty-day vein remodeling is predictive of midterm graft patency after lower extremity bypass. <i>Journal of Vascular Surgery</i> , 2013, 57, 9-18.	1.1	32
119	Growing Impact of Restenosis on the Surgical Treatment of Peripheral Arterial Disease. <i>Journal of the American Heart Association</i> , 2013, 2, e000345.	3.7	52
120	A single nucleotide polymorphism in the p27Kip1 gene is associated with primary patency of lower extremity vein bypass grafts. <i>Journal of Vascular Surgery</i> , 2013, 57, 1179-1185.e2.	1.1	18
121	Dâ€series resolvin attenuates vascular smooth muscle cell activation and neointimal hyperplasia following vascular injury. <i>FASEB Journal</i> , 2013, 27, 2220-2232.	0.5	112
122	Abstract 17: The Association Between Erythrocyte n-3 Polyunsaturated Fatty Acids (n-3 PUFAs) Content and Inflammation in Male Patients With Peripheral Artery Disease (PAD). <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, .	2.4	0
123	Abstract 251: Effects of n-3 Fatty Acids Supplementation on Endothelial Function and Inflammation in Peripheral Artery Disease: The OMEGA-PAD Trial. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, .	2.4	0
124	Risk factors for clinical failure after stent graft treatment for femoropopliteal occlusive disease. <i>Journal of Vascular Surgery</i> , 2012, 56, 998-1007.e1.	1.1	32
125	An integrated biochemical prediction model of all-cause mortality in patients undergoing lower extremity bypass surgery for advanced peripheral artery disease. <i>Journal of Vascular Surgery</i> , 2012, 56, 686-695.	1.1	31
126	Diabetic Revascularization: Endovascular Versus Open Bypassâ€”Do We Have the Answer?. <i>Seminars in Vascular Surgery</i> , 2012, 25, 108-114.	2.8	51

#	ARTICLE	IF	CITATIONS
127	Acute Limb Ischemia. New England Journal of Medicine, 2012, 366, 2198-2206.	27.0	273
128	Chemical Mediators of Inflammation and Resolution in Post-Operative Abdominal Aortic Aneurysm Patients. Inflammation, 2012, 35, 98-113.	3.8	49
129	Influence of diabetes and perivascular allogeneic endothelial cell implants on arteriovenous fistula remodeling. Journal of Vascular Surgery, 2011, 54, 1383-1389.	1.1	39
130	Discussion: Open Surgical Revascularization for Wound Healing: Past Performance and Future Directions; and Discussion: Critical Evaluation of Endovascular Surgery for Limb Salvage. Plastic and Reconstructive Surgery, 2011, 127, 174S-176S.	1.4	1
131	Challenges of Distal Bypass Surgery in Patients with Diabetes. Journal of the American Podiatric Medical Association, 2010, 100, 429-438.	0.3	8
132	Understanding Objective Performance Goals for Critical Limb Ischemia Trials. Seminars in Vascular Surgery, 2010, 23, 129-137.	2.8	75
133	Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) and the (hoped for) dawn of evidence-based treatment for advanced limb ischemia. Journal of Vascular Surgery, 2010, 51, 69S-75S.	1.1	103
134	Challenges of distal bypass surgery in patients with diabetes: Patient selection, techniques, and outcomes. Journal of Vascular Surgery, 2010, 52, 96S-103S.	1.1	40
135	Aspirin-Triggered Lipoxin and Resolvin E1 Modulate Vascular Smooth Muscle Phenotype and Correlate with Peripheral Atherosclerosis. American Journal of Pathology, 2010, 177, 2116-2123.	3.8	178
136	Disparity in Outcomes of Surgical Revascularization for Limb Salvage. Circulation, 2009, 119, 123-130.	1.6	165
137	Technical Factors in Lower-Extremity Vein Bypass Surgery: How Can We Improve Outcomes?. Seminars in Vascular Surgery, 2009, 22, 227-233.	2.8	36
138	Multicenter phase I/II trial of the safety of allogeneic endothelial cell implants after the creation of arteriovenous access for hemodialysis use: The V-HEALTH study. Journal of Vascular Surgery, 2009, 50, 1359-1368.e1.	1.1	71
139	Suggested objective performance goals and clinical trial design for evaluating catheter-based treatment of critical limb ischemia. Journal of Vascular Surgery, 2009, 50, 1462-1473.e3.	1.1	383
140	Statins are independently associated with reduced mortality in patients undergoing infrainguinal bypass graft surgery for critical limb ischemia. Journal of Vascular Surgery, 2008, 47, 774-781.e1.	1.1	142
141	Risk stratification in critical limb ischemia: Derivation and validation of a model to predict amputation-free survival using multicenter surgical outcomes data. Journal of Vascular Surgery, 2008, 48, 1464-1471.	1.1	227
142	C-reactive protein and vein graft disease: evidence for a direct effect on smooth muscle cell phenotype via modulation of PDGF receptor- β . American Journal of Physiology - Heart and Circulatory Physiology, 2008, 295, H1132-H1140.	3.2	16
143	Molecular engineering of vein bypass grafts. Journal of Vascular Surgery, 2007, 45, A74-A81.	1.1	32
144	Superficial femoral artery percutaneous intervention is an effective strategy to optimize inflow for distal origin bypass grafts. Journal of Vascular Surgery, 2007, 45, 740-743.	1.1	28

#	ARTICLE	IF	CITATIONS
145	Elevated C-reactive protein levels are associated with postoperative events in patients undergoing lower extremity vein bypass surgery. <i>Journal of Vascular Surgery</i> , 2007, 45, 2-9.	1.1	141
146	Refinement of survival prediction in patients undergoing lower extremity bypass surgery: Stratification by chronic kidney disease classification. <i>Journal of Vascular Surgery</i> , 2007, 45, 944-952.	1.1	125
147	Technical factors affecting autogenous vein graft failure: Observations from a large multicenter trial. <i>Journal of Vascular Surgery</i> , 2007, 46, 1180-1190.	1.1	211
148	Resource utilization in the treatment of critical limb ischemia: the effect of tissue loss, comorbidities, and graft-related events. <i>Journal of Vascular Surgery</i> , 2006, 44, 971-975.	1.1	39
149	Results of PREVENT III: A multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. <i>Journal of Vascular Surgery</i> , 2006, 43, 742-751.e1.	1.1	579
150	Prospective multicenter study of quality of life before and after lower extremity vein bypass in 1404 patients with critical limb ischemia. <i>Journal of Vascular Surgery</i> , 2006, 44, 977-983.	1.1	116
151	Survivin Regulation of Vascular Injury. <i>Trends in Cardiovascular Medicine</i> , 2006, 16, 114-117.	4.9	15
152	Design and Rationale of the PREVENT III Clinical Trial: Edifoligide for the Prevention of Infrainguinal Vein Graft Failure. <i>Vascular and Endovascular Surgery</i> , 2005, 39, 15-23.	0.7	52
153	Regulation of Vein Graft Hyperplasia by Survivin, an Inhibitor of Apoptosis Protein. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 2081-2087.	2.4	46
154	Risk factors, medical therapies and perioperative events in limb salvage surgery: Observations from the PREVENT III multicenter trial. <i>Journal of Vascular Surgery</i> , 2005, 42, 456-464.	1.1	149
155	Survivin expression is up-regulated in vascular injury and identifies a distinct cellular phenotype. <i>Journal of Vascular Surgery</i> , 2005, 41, 682-690.	1.1	30
156	Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts. <i>Journal of Vascular Surgery</i> , 2004, 39, 1178-1185.	1.1	168
157	Infrainguinal vein bypass graft revision: Factors affecting long-term outcome. <i>Journal of Vascular Surgery</i> , 2004, 40, 916-923.	1.1	99
158	The impact of patient age and aortic size on the results of aortobifemoral bypass grafting ¹ 1Competition of interest: none. Published online Mar 6, 2003. <i>Journal of Vascular Surgery</i> , 2003, 37, 1219-1225.	1.1	88
159	Usefulness of autogenous bypass grafts originating distal to the groin. <i>Journal of Vascular Surgery</i> , 2002, 35, 48-55.	1.1	34
160	Genetic interventions for vein bypass graft disease: A review. <i>Journal of Vascular Surgery</i> , 2002, 36, 1040-1052.	1.1	41
161	Infrainguinal bypass grafting in patients with end-stage renal disease: Improving outcomes?. <i>Journal of Vascular Surgery</i> , 2001, 33, 1171-1178.	1.1	73
162	The ideal small arterial substitute: a search for the Holy Grail?. <i>FASEB Journal</i> , 1998, 12, 43-45.	0.5	218

#	ARTICLE	IF	CITATIONS
163	The ideal small arterial substitute: a search for the Holy Grail?. FASEB Journal, 1998, 12, 43-45.	0.5	59